// App-Quantinova.ai

: NOVA-II: Part 2 study to evaluate the safety and efficacy of OQL011 on VEGF inhibitor-associated hand-foot skin reaction in patients with cancer.

Researchers

Presenter

  • Anisha B Patel

Principal Investigators

  • Milan J. Anadkat

  • Omkar Subhash Marathe

  • Mark L Webb

  • Robert Claude Tyler

  • Wenhui Zhang

  • Chengguang Wu

  • Juegang Ju

  • Hong Tang

  • Jie Luo

  • Mario E. Lacouture

Medical Centers

  • 1.MD Anderson Cancer Center, Houston, TX

  • OnQuality Pharmaceuticals, Seattle, WA

  • Memorial Sloan Kettering Cancer Center, Port Washington, NY

  • Division of Oncology, Washington University School of Medicine, St. Louis, MO

  • Oncology Institute of Hope & Innovation, Long Beach, CA

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Dermatology

Disease

  • Hand-foot skin reaction

  • Solid malignancies

Biomarkers

  • Vascular endothelial growth factor A

Drug/Treatment

  • Nitroglycerin

  • Adesitrin

  • Cabozantinib

  • Nitric oxide

  • Regorafenib

  • Sunitinib

  • Sorafenib

  • L-Tyrosine

Outcome

  • N/A

Study Design

  • Randomized

  • Pharmacokinetics

  • Double Blind/Blinded

  • Superiority

  • Controlled

Phase

  • II

Study Id's

  • NCT04088318

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved